53 results about "LILRB2" patented technology

The present invention provides antibodies, or antigen binding fragments thereof, capable of binding to leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). The invention also provides application of the antibody or the antigen binding fragment thereof in preparation of drugs for treating diseases related to high expression of LILRB2. The antibody or the antigen binding fragment thereof provided by the invention can bind to human LILRB2 with high affinity, block the binding of the LILRB2 and the ligand HLA-G thereof, and enhance the T cell function.

Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

The invention relates to antigen binding proteins, such as antibodies, that bind to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRBI) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA), which can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of LILRB receptors (interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. In particular, the invention provides products, compositions and methods for treating diseases using antigen binding proteins of LILRB1 and / or LILRB2, especially antigen binding proteins which while, preferably specifically, binding to LILRB1 and LILRB2, such as antigen binding proteins that further do not bind to, or bind with less affinity to, one or more LILRA receptor proteins (such as LILRA1 and / or LILRA3). Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

The disclosure relates to methods for treating cancer with LILRB2 antibody products.

The present invention relates to antibodies, or antigen-binding fragments thereof, that are capable of binding to Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2). The present invention also relates to methods of producing and therapeutic uses of such antibodies, or antigen-binding fragments thereof.

The present invention relates to antigen-binding proteins, such as antibodies, that bind to leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 without binding or with significantly lower affinity to leukocyte immunoglobulin-like receptor subfamily A (LILRA), which can also inhibit the interaction between LILRB1 and / or LILRB2 and a native ligand of the LILRB receptor (interacting protein, such as HLA-G) on an immune cell, such as LILRB1 and LILRB2. And the inhibition of the interaction can reduce the inhibition of immune cells, thereby supporting the anti-infection and anti-tumor immune response of subjects suffering from the disease. In particular, the present invention provides products, compositions and methods for treating disease using antigen binding proteins of LILRB1 and / or LILRB2, particularly antigen binding proteins that preferably specifically bind to LILRB1 and LILRB2, such as antigen binding proteins that further do not bind or bind with lower affinity to one or more LILRA receptor proteins (e.g., LILRA1 and / or LILRA3). Also provided are methods of using LILRB1 and / or LILRB2 antigen binding proteins, such as antibodies that bind to LILRB1 and / or LILRB2, to reduce immunosuppression of cells involved in a cell-mediated immune response and / or to treat infectious and / or proliferative diseases, as well as certain related aspects, including methods of detection, diagnosis, and screening.

The present disclosure relates to LILRB2 antibody products and methods of use thereof. The antibody product specifically binds to LILRB2 on cells, such as myeloid cells or cancer cells. The antibody products can be used in methods of treating disease, such as methods of cancer immunotherapy.

Provided herein are methods of improving sensitivity to immune checkpoint blockade (ICB) in a subject with a solid tumor cancer, the method comprising: administering to the subject with a solid tumor cancer an inhibitor of a tumor immune microenvironment (TIME) gene, wherein the TIME gene is selected from the group consisting of SLC11A1, CCBL2, LILRB2, LILRB4, LAIR1, CTSS, CTSW, B2M, HAUS1, MS4A4A, FCGR2B, LYZ, and GNPTAB, thereby improving sensitivity to ICB in the subject with a solid tumor cancer.

Provided are an HLA-G-targeting antibody or an antigen-binding fragment thereof and a use thereof, relating to the field of antibodies. The antibody or the antigen-binding fragment thereof comprises: a heavy-chain complementarity determining region (HCDR) and a light-chain complementarity determining region (LCDR), wherein the HCDR comprises at least one sequence selected from SEQ ID NOs: 1-6 or an amino acid sequence having at least 80% homology with the sequence; and the LCDR comprises at least one sequence selected from SEQ ID NOs: 7-12 or an amino acid sequence having at least 80% homology with the sequence. The antibody or antigen-binding fragment has high specificity and high affinity, can bind to human and cynomolgus monkey HLA-G and specifically block binding of HLA-G to receptors LILRB1 and LILRB2 thereof, and promotes a killing effect of immune cells on tumor cells, thereby effectively treating and / or preventing HLA-G-mediated related diseases, such as tumors.

The disclosure relates to LILRB2 / 1 antibody products and methods of use thereof. The antibody products specifically bind to LILRB1 and LILRB2 on cells such as myeloid cells, lymphocytes, or cancer cells. The antibody products can be used in methods of treatment of disease, such as methods cancer immunotherapy.

Disclosed herein are antibodies and antigen-binding domains that specifically bind to human CD98 heavy chain (CD98hc) and their use in, for example, transport across the blood brain barrier (BBB). Among others, bispecific antibodies targeting CD98hc and LILRB2 and their uses in, for example, treating neurological diseases are also provided.

In certain aspects, the subject matter disclosed herein relates to high affinity monoclonal antibodies against LILRB4 and / or LILRB2 and their use in inhibiting myeloid-dependent, immune-suppressive signals and in cancer treatment. In certain aspects, the subject matter disclosed herein relates to bispecific molecules binding LILRB4 and LILRB2.

The present invention relates to single domain antibodies (sdAbs) against leukocyte immunoglobulin-like receptor subfamily B, member 2 (LILRB2), pharmaceutical compositions comprising the same, and uses thereof in diagnosis and treatment.

The present disclosure provides antibodies that bind to LILB1 and LILRB2, and methods of using them to enhance immunity in a patient in need thereof and to treat cancer.

The present disclosure provides antibodies, or antigen-binding fragments thereof, that bind to LILRB2 (leukocyte immunoglobulin-like receptor B2), which can block the signaling pathway and up-regulate the immune response to LILRB2-related diseases, disorders, or conditions.

An antibody that can specifically bind to semenogelin-1 (SEMG1) and semenogelin-2 (SEMG2) and regulate the binding of said proteins with a receptor (LILRB2, LILRB4, CD27, or TIGIT) thereof. It is proven that SEMG1 and SEMG2 have a regulating effect on immune cells, and it is proven that the antibody has a neutralizing effect. A specific linear epitope located on SEMG1 and SEMG2 proteins is provided, and it is proven that an antibody recognizing said epitope has a stronger neutralizing function, can more effectively remove an immunosuppressive effect mediated by SEMG1 and SEMG2, and promotes immune cells to inhibit and kill tumor cells. Further provided are preparation and identification methods for the antibody as well as a biomarker for the administration of such antibody. The present invention has good application prospects in the aspect of preparation of an anti-tumor drug.

The present invention provides antibodies that specifically bind to immunoglobulin-like transcript 4 (ILT4), also known as LILRB2, LIR2, MIR10, and CD85d, as well as corresponding nucleic acids, host cells, compositions, and uses. [Solution] An isolated antibody is provided that specifically binds to human ILT4 (hILT4 or ILT4), specifically binding to human ILT4 but not significantly binding to ILT2, ILT3, or ILT5, or other members of the LILRA or LILRB family.

The invention provides an HLA-G targeting antibody or an antigen binding fragment thereof and application thereof, and relates to the field of antibodies. Wherein the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR and a light chain complementarity determining region LCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-6 or an amino acid sequence having at least 80% homology with the HCDR; the LCDR comprises at least one of SEQ ID NO: 7-12 or an amino acid sequence having at least 80% homology with the at least one of SEQ ID NO: 7-12. The antibody or the antigen binding fragment has high specificity and high affinity, can bind to human and cynomolgus monkey HLA-G, specifically blocks the binding of the HLA-G and its receptors LILRB1 and LILRB2, promotes the killing of immune cells to tumor cells, and effectively treats and / or prevents HLA-G mediated related diseases, such as tumors.

The present invention relates to an anti-LILRB2 antibody and its use. The anti-LILRB2 antibody provided by the present invention has high affinity for human LILRB2 and can block the interaction between LILRB1 and the ligand HLA-G.

Disclosed herein are antibodies and antigen-binding domains that specifically bind to human CD98 heavy chain (CD98hc) and their use in, for example, transport across the blood brain barrier (BBB). Among others, bispecific antibodies targeting CD98hc and LILRB2 and their uses in, for example, treating neurological diseases are also provided.

Provided herein are antibodies and antigen-binding fragments thereof against LILRB1 and / or LILRB2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to LILRB1 and / or LILRB2 activate tumor-infiltrating immune cells and enhance their anti-tumor effect. Also provided are methods for treating LILRB1 and / or LILRB2 expressing cancer by administering the antibody or antigen-binding fragment thereof that specifically bind to LILRB1 and / or LILRB2.

The invention belongs to the field of biological medicine, and particularly relates to a bispecific antibody and application thereof. The bispecific antibody comprises a first antigen binding protein and a second antigen binding protein, wherein the first antigen binding protein is connected with the second antigen binding protein; the first antigen binding protein is used for binding HLAG protein, and the second antigen binding protein is used for binding PDL1 protein. According to the present invention, the bispecific antibody can be combined with PDL1 and HLAG, and can block HLAG-LILRB1 / LILRB2 signal and PD1-PDL1 signal channels so as to promote T cell activation, effectively promote immune cells to kill tumor cells, and has good anti-cancer activity. Therefore, the bispecific antibody disclosed by the invention has good clinical application and drug development values, and especially can be used for effectively treating cancers.

An antigen-binding protein capable of binding specifically to human LILRB1 and to human LILRB2, wherein the antigen-binding protein does not block the interaction of human LILRB1 with HLA-G tetramer and / or does not block the interaction of human LILRB2 with HLA-G tetramer, and the antigen-binding protein is capable of reprogramming macrophage.